OTTAWA, March 17
/PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS;
http://www.htdsmedical.com/) Collagenna Skin Care Products will
commence shipments to Brazil
shortly.
Collagenna Skin Products has received its first major order for
shipments to its distribution partner Collagenna do Brasil.
Collagenna's CEO Michael Arnkvarn
states: "As I have mentioned in the past, this has been an
unusually long process in order to get past the bureaucratic maze
to send products to probably one of the most protected markets in
the world. But we have persisted and our main client has remained
patient and committed to offering the Collagenna Product line to
their customers. We will now be able to ship on a monthly basis and
we expect the volume to double by this year's fourth quarter. The
fact remains that the Purchase Order we have received is the single
largest order in our history. This is the first of many more to
come and we are committed to expanding our international and
domestic markets."
Over 600 products have been ordered with a retail value of
approximately $36,000. The order is
expected to be expedited by the end of March
2010.
The company reminds our shareholders and followers to monitor
PinkSheets.com Filing Section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/. Non-newsworthy events are not press
released however posted on these two separate support sites to keep
our followers advised of day-to-day events. For any matters
relating to retail investor queries or to send the company a direct
message please click on the "INVESTOR SUPPORT" TAB or this direct
link http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful
that short sellers, the company's competitors and stock bashers
stalk small cap Pink Sheets listed companies with hidden agendas,
where amongst other things they continuously spread false rumors,
dark propaganda and innuendos in order to manipulate the trading
patterns and thwart company plans for their own "quick profits" and
self serving needs. The company and its supporters are monitoring
these activities and those are promptly being reported on the
http://www.stockbasher.com website. Visit
http://www.stockbasher.com and find out what criminal and civil
actions the US authorities are taking against web sites like
investorshub.com and other posters, and other media that provide
safe refuge to these individuals and the remedies available to you
as an individual investor.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support Section in due course. To
be included in the company's email database for press releases,
industry updates, and non-weekly activity at the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
